In brief: Biodiem; Avexa
Tuesday, 11 January, 2005
BioDiem (ASX:BDM) has received a US$1m signing-on payment, the first in a number of milestone payments due under its US$8m licence agreement with Akzo Nobel's Nobilon.
Avexa antibacterial studies confirmed
Maryland-based company ImQuest BioSciences has confirmed the activity of Avexa's (ASX: AVX) antibacterial compounds against vancomycin-resistant enterococci (VRE).
Avexa aims to have a lead compound in proof-of-concept models by the end of 2005.
Link between oestrogen and heart health found in women
Scientists found that oestrogen helps increase the ANXA1 protein, and when ANXA1 is missing, the...
Frequent nightmares accelerate aging, increase risk of death
Nghtmares independently predict faster biological aging and earlier mortality — even after...
Cardiac organoids bring hope for treating heart disease
Australian scientists have developed lab-grown, three-dimensional heart tissues known as cardiac...
